Recombinant Human Probable palmitoyltransferase ZDHHC12 (ZDHHC12)

What is ZDHHC12 and what is its fundamental cellular function?

ZDHHC12 is a palmitoyl transferase enzyme involved in protein palmitoylation, a critical post-translational modification. This enzyme plays a key role in the regulation of protein localization, stability, and function through the addition of palmitate groups to protein substrates . ZDHHC12 belongs to the ZDHHC family of genes, which in mammals consists of 23 members . The enzyme contains the characteristic Asp-His-His-Cys (DHHC) catalytic domain responsible for its palmitoyltransferase activity. Dysregulation of palmitoylation has been associated with various diseases, including cancer, neurological disorders, and metabolic conditions . Understanding ZDHHC12 function is essential for unraveling the molecular mechanisms underlying these pathologies.

What methodological approaches are most effective for detecting and measuring ZDHHC12 in experimental systems?

Several methodologies are available for researchers to detect and analyze ZDHHC12:

For optimal results, researchers should use antibodies targeting recombinant human ZDHHC12 protein, particularly the region spanning amino acids 121-197 . The ZDHHC12 Polyclonal Antibody exhibits high specificity and sensitivity towards human samples and has been validated for multiple applications. Preservation in 0.03% Proclin 300 with 50% Glycerol and 0.01M PBS (pH 7.4) maintains antibody stability and function .

What structural features and domains characterize the ZDHHC12 protein?

ZDHHC12 contains the signature DHHC domain that defines this family of palmitoyltransferases. The catalytic cysteine at position 127 is critical for enzymatic activity, as demonstrated by the loss of function in the C127S mutant . This residue is essential for the transfer of palmitate groups to substrate proteins. The protein's structural organization allows for specific substrate recognition and catalytic efficiency. Mutation studies have confirmed that the C127S substitution abolishes palmitoyltransferase activity while maintaining protein-protein interactions, making this mutation valuable for mechanistic studies of ZDHHC12 function .

What are the known substrate proteins of ZDHHC12 and how does it regulate their function?

Current research has identified claudin-3 (CLDN3) as a key substrate of ZDHHC12. The enzyme mediates S-palmitoylation of CLDN3 specifically at cysteine residues 181, 182, and 184 in the C-terminus region . This post-translational modification is critical for:

• Proper membrane localization of CLDN3

• Maintaining CLDN3 protein stability

• Supporting CLDN3's function in cell signaling

Experimental evidence demonstrates that co-expression of wild-type ZDHHC12 with CLDN3 increases the S-palmitoylation level of CLDN3 by approximately 1.40-fold compared to cells expressing CLDN3 alone . Conversely, knockdown of ZDHHC12 results in approximately 50% decrease in S-palmitoylation of CLDN3, confirming ZDHHC12 as the dominant enzyme responsible for CLDN3 palmitoylation .

How does ZDHHC12-mediated palmitoylation impact protein trafficking and localization?

ZDHHC12-mediated palmitoylation plays a crucial role in determining protein subcellular localization, particularly for membrane proteins. In the case of CLDN3:

• Proper S-palmitoylation by ZDHHC12 facilitates cytomembrane targeting of CLDN3

• When ZDHHC12 is knocked down, CLDN3 shows insufficient S-palmitoylation leading to intracellular distribution rather than membrane localization

• Confocal microscopy reveals that ZDHHC12 knockdown hinders CLDN3 targeting to the cytomembrane, resulting in partial intracellular mislocalization

Quantitative analysis of colocalization between CLDN3 and ZO-1 (a tight junction protein) further demonstrates that ZDHHC12 knockdown significantly reduces their colocalization at cell junctions . This evidence indicates that ZDHHC12-mediated palmitoylation serves as a molecular switch that determines whether proteins like CLDN3 properly localize to their functional sites or remain mislocalized within the cell.

What is the role of ZDHHC12 in cancer progression and how is it dysregulated in malignancies?

ZDHHC12 exhibits oncogenic properties in several cancer types, with particularly strong evidence in ovarian cancer:

• Analysis of The Cancer Genome Atlas (TCGA) data reveals significantly elevated ZDHHC12 expression in ovarian cancer tissues

• Among all ZDHHC enzymes, ZDHHC12 demonstrates the strongest positive association with reactive oxygen species (ROS) pathways in ovarian cancer

• Transcriptomic analysis of ovarian cancer datasets shows a robust link between ZDHHC12 expression and signature pathways involving mitochondrial oxidative metabolism and ROS regulation

The oncogenic function of ZDHHC12 appears to operate through multiple mechanisms:

• Promotion of cancer cell proliferation and tumor growth

• Regulation of mitochondrial function and ROS homeostasis

• Stabilization of oncoproteins like CLDN3 through palmitoylation

• Activation of pro-tumorigenic signaling pathways, including MAPK/ERK

In vivo studies demonstrated that silencing ZDHHC12 significantly inhibits tumorigenesis and tumor growth in ovarian cancer xenograft models . When OVCAR8 cells with shRNA targeting ZDHHC12 were implanted in BALB/c-nu mice, the tumorigenesis and growth rate were substantially slower than in control groups .

How does ZDHHC12 contribute to mitochondrial function and reactive oxygen species (ROS) regulation?

ZDHHC12 plays a critical role in maintaining mitochondrial homeostasis and ROS balance in cancer cells:

• ZDHHC12 expression strongly correlates with mitochondrial oxidative metabolism pathways in ovarian cancer

• Knockdown of ZDHHC12 leads to:

  • Increased cellular complexity

  • Elevated ATP levels

  • Enhanced mitochondrial activity

  • Increased both mitochondrial and cellular ROS levels

This dysregulation of mitochondrial function and ROS homeostasis represents a key mechanism by which ZDHHC12 influences cancer cell biology. While the precise molecular targets mediating these effects require further characterization, the data suggest ZDHHC12 acts as a master regulator of cancer cell metabolism and redox balance .

How can targeting ZDHHC12 enhance chemotherapy efficacy in cancer treatment?

Inhibition of ZDHHC12 shows significant promise as a strategy to improve chemotherapy response, particularly for platinum-based treatments in ovarian cancer:

The mechanism involves disruption of ROS homeostasis in cancer cells, leading to increased cellular and mitochondrial ROS levels that potentiate cisplatin-induced cytotoxicity . Importantly, ZDHHC12 inhibition significantly enhanced the anti-tumor activity of cisplatin in an ovarian cancer xenograft tumor model and in an ascites-derived organoid line of platinum-resistant ovarian cancer .

These findings have significant clinical implications, suggesting that targeting ZDHHC12 could represent a novel approach to overcome chemotherapy resistance in aggressive cancers like high-grade serous ovarian cancer (HGSOC).

What is the relationship between ZDHHC12 and CLDN3 in ovarian cancer tumorigenesis?

ZDHHC12 and CLDN3 exhibit a functionally significant relationship in ovarian cancer:

• ZDHHC12 mediates S-palmitoylation of CLDN3 on multiple cysteines (Cys181, Cys182, and Cys184) in its C-terminus region

• This palmitoylation is essential for CLDN3's oncogenic function:

  • Promotes proper membrane localization of CLDN3

  • Maintains CLDN3 protein stability

  • Activates downstream signaling pathways including MAPK/ERK

• Clinical evidence shows a positive correlation between ZDHHC12 and CLDN3 expression in ovarian cancer samples at both protein and mRNA levels

When ZDHHC12 is knocked down, CLDN3 shows insufficient S-palmitoylation, leading to:

• Intracellular mislocalization rather than membrane targeting

• Increased susceptibility to degradation

• Diminished activation of oncogenic signaling pathways

• Reduced tumor growth in experimental models

This relationship represents a mechanistic explanation for how ZDHHC12 promotes ovarian cancer progression and identifies the ZDHHC12-CLDN3 axis as a potential therapeutic target.

What are the key considerations for generating and working with recombinant ZDHHC12 protein?

When working with recombinant ZDHHC12, researchers should consider:

• Expression system selection: Mammalian expression systems are often preferred for ensuring proper folding and post-translational modifications of human ZDHHC12

• Purification strategy: Affinity purification methods yield high-purity preparations suitable for enzymatic and structural studies

• Storage conditions: 50% Glycerol, 0.01M PBS at pH 7.4 with 0.03% Proclin 300 preservative maintains protein stability

• Activity assessment: Functional assays measuring palmitoyltransferase activity are essential to confirm the enzymatic competence of recombinant preparations

Different species variants of ZDHHC12 (human, cynomolgus/rhesus macaque, rat, mouse, feline, canine, bovine, and equine) are available for comparative studies , allowing researchers to investigate species-specific differences in ZDHHC12 function and regulation.

What challenges exist in developing specific inhibitors of ZDHHC12 for research and therapeutic applications?

Development of specific ZDHHC12 inhibitors faces several challenges:

• Selectivity across ZDHHC family: The ZDHHC family comprises 23 members with similar catalytic domains, making selective targeting difficult

• Structural information: Limited high-resolution structural data for ZDHHC12 hampers structure-based drug design

• Assay development: Establishing high-throughput screening assays specific for ZDHHC12 activity

• In vivo validation: Confirming target engagement and specificity in complex biological systems

Current approaches rely on general palmitoylation inhibitors like 2-bromopalmitate (2BP) or indirect strategies like fatty acid synthase inhibition with C75 . While these approaches have demonstrated efficacy in experimental models, development of ZDHHC12-specific inhibitors remains an important goal for both research and potential therapeutic applications.

What are the future directions for ZDHHC12 research and its potential clinical applications?

Future research on ZDHHC12 should address several key areas:

• Comprehensive substrate identification: Beyond CLDN3, identifying the complete set of ZDHHC12 substrates will provide deeper insights into its biological functions

• Structural characterization: High-resolution structural studies of ZDHHC12 will facilitate rational drug design

• Tissue-specific functions: Understanding ZDHHC12's role across different tissues and cell types, particularly in the nervous system where expression patterns vary significantly

• Development of specific inhibitors: Creating selective ZDHHC12 inhibitors for research and potential therapeutic applications

• Combination therapy optimization: Determining optimal combinations of ZDHHC12 inhibition with standard chemotherapies for maximal clinical benefit

• Biomarker development: Identifying biomarkers that predict response to ZDHHC12-targeting strategies